DOI: https://doi.org/10.36347/sajb.2025.v13i02.009

Pages: 298-302

Background: Psoriasis is a T-cell driven inflammatory skin disorder which has a complex genetic background. Till date >86 psoriasis susceptibility loci have located, among which HLA-C*06 is the most strongly associated with a global prevalence ranging from 10.5% to 77.2% in psoriatic patients. Carriers of HLA-C*06 have distinct clinical phenotype with an early onset, worse disease progression but less chance of developing psoriatic arthritis and cardiovascular comorbidities. Moreover, better response with methotrexate and certain biologics are noted in HLA-C*06 carrier patients. This study aims to evaluate frequency of HLA-C susceptible alleles in psoriatic patients and in normal population by PCR and to observe the association of HLAC 06 with age of onset, gender, BMI, pattern & severity of psoriasis by statistical analysis. Methods: This study took place in the department of Dermatology and Venereology department of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh over a period from July 2021 to June 2022 In total 40 psoriasis (diagnosed based on history, clinical symptoms, and/or histological report) along with 40 apparently healthy controls fulfilling the inclusion and exclusion criteria were enrolled following consecutive sampling procedure. Blood samples were collected to determine HLA-C alleles by PCR at the Department of Microbiology & Immunology. Result was analyzed with SPSS software package version-26. Results: The controls were 36.8 ±14.2 years old, whereas the patients were 30.5± 15.8 years old on average. Plaque psoriasis was most prevalent, occurring among 75% of the case. Psoriasis patients had BMIs that were considerably higher than those of the controls. The most prevalent alleles were HLA-C*06 (47.5%) and HLA-C*07 (57.5%) in psoriasis patients and HLA-C*8 (40%) in controls. Female patients had a substantially greater frequency of HLA-C*06. There was no correlation found between HLA-C*06 and the patient's BMI,age of onset, pso